Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 377

1.

Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.

Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G, Horninger W.

Urology. 2007 Jan;69(1):134-8.

PMID:
17270635
2.

Prostate-specific antigen velocity and prostate cancer gleason grade and stage.

Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.

Cancer. 2007 Apr 15;109(8):1689-95.

3.

Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.

Berger AP, Deibl M, Strasak A, Bektic J, Pelzer A, Steiner H, Spranger R, Fritsche G, Bartsch G, Horninger W.

Urology. 2006 Nov;68(5):1067-71. Epub 2006 Nov 7.

PMID:
17095070
4.

Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations.

Ito K, Kubota Y, Suzuki K, Shimizu N, Fukabori Y, Kurokawa K, Imai K, Yamanaka H.

Urology. 2000 May;55(5):705-9.

PMID:
10792085
5.

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.

Prostate. 2005 Aug 1;64(3):240-5.

PMID:
15712213
6.

Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.

Bittner N, Merrick GS, Andreini H, Taubenslag W, Allen ZA, Butler WM, Anderson RL, Adamovich E, Wallner KE.

Urology. 2009 Jul;74(1):171-6. doi: 10.1016/j.urology.2008.12.013. Epub 2009 Feb 20.

PMID:
19232691
7.

The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.

Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, D'Amico AV.

Cancer. 2008 Aug 15;113(4):717-22. doi: 10.1002/cncr.23609.

8.

Usefulness of prostate-specific antigen velocity in screening for prostate cancer.

Ito K, Yamamoto T, Ohi M, Kubota Y, Fukabori Y, Kurokawa K, Suzuki K, Yamanaka H.

Int J Urol. 2002 Jun;9(6):316-21.

9.

PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.

Loeb S, Sutherland DE, D'Amico AV, Roehl KA, Catalona WJ.

Urology. 2008 Nov;72(5):1116-20; discussion 1120. doi: 10.1016/j.urology.2008.01.082. Epub 2008 Jun 24.

PMID:
18571700
10.

Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.

Takechi H, Ito K, Yamamoto T, Miyakubo M, Ohi M, Suzuki K.

Urology. 2008 Nov;72(5):1111-5. doi: 10.1016/j.urology.2007.12.090. Epub 2008 Mar 17.

PMID:
18342926
11.

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml.

Fang J, Metter EJ, Landis P, Carter HB.

Urology. 2002 Jun;59(6):889-93; discussion 893-4.

PMID:
12031375
12.

Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, Fitzsimons N, Albala D, Polascik TJ.

BJU Int. 2007 Apr;99(4):753-7. Epub 2007 Jan 19.

13.
14.
15.

Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.

King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC Jr.

Urology. 2007 Apr;69(4):732-7.

PMID:
17445660
16.

The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.

Connolly D, Black A, Murray LJ, Nambirajan T, Keane PF, Gavin A.

BJU Int. 2008 Jun;101(12):1507-12. doi: 10.1111/j.1464-410X.2008.07470.x. Epub 2008 Mar 13.

17.

Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer.

Thiel R, Pearson JD, Epstein JI, Walsh PC, Carter HB.

Urology. 1997 May;49(5):716-20.

PMID:
9145976
18.

Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.

King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr.

Urology. 2007 May;69(5):921-6.

PMID:
17482935
19.

Prostate-specific antigen velocity in healthy Korean men with initial PSA levels of 4.0 ng/mL or less.

Ham WS, Kang DR, Kim YS, Seong do H, Kim SJ, Cheon SH, Cho IR, Cho JS, Kim CI, Choi YD.

Urology. 2008 Jul;72(1):99-103. doi: 10.1016/j.urology.2008.03.002. Epub 2008 Jun 4.

PMID:
18533237
20.

Supplemental Content

Support Center